← Back to Clinical Trials
Recruiting NCT06545877

REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Infertility
Sponsor Ferring Pharmaceuticals
Study Type OBSERVATIONAL
Phase N/A
Enrollment 500
Sex FEMALE
Min Age N/A
Max Age N/A
Start Date 2022-09-16
Completion 2026-02-28

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This survey targets controlled ovarian stimulation with this drug for the development of multiple oocytes in women undergoing assisted reproduction (ART) such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Eligibility Criteria

Inclusion Criteria: * Participants who received the REKOVELLE in controlled ovarian stimulation in assisted reproductive technologies and have consented to participate in the survey. Exclusion Criteria: * No exclusion criteria because data are collected under conditions of use in daily practice.

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE INFERTILITY TRIALS
}
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology